Skip to main content
Toggle navigation
Login
Search
Home
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Live Streamed
On Demand
Back
Favorite
Facebook
Tweet
Print
Abigail Scullin, BS
Element Materials Technology/Jones Microbiology Institute
Poster(s):
(P-1059)
In vitro
Activity of Gepotidacin against
Klebsiella pneumoniae
, Including Molecularly Characterized ESBL and Carbapenemase positive Subsets Causing Urinary Tract Infections in the United States (2019-2022)
Friday, October 18, 2024
12:15 PM – 1:30 PM
US PT
(P-1060)
In vitro
Activity of Gepotidacin Tested Against Molecularly Characterized
Escherichia coli
Isolates Responsible for Urinary Tract Infections in the US (2019-2022)
Friday, October 18, 2024
12:15 PM – 1:30 PM
US PT
(P-1361) Cefiderocol Activity against
Pseudomonas aeruginosa
, Including Resistant Subsets and Isolates Carrying Carbapenemase β-lactamase Genes, from United States Hospitals (2020–2023)
Friday, October 18, 2024
12:15 PM – 1:30 PM
US PT
(P-1362) Cefiderocol Activity against Carbapenem-resistant
Acinetobacter baumannii-calcoaceticus
complex, Including Molecularly Characterized Clinical Isolates, Causing Infections in United States Hospitals (2020–2023)
Friday, October 18, 2024
12:15 PM – 1:30 PM
US PT